Advertisement
"This patent is the result of our collaboration with Dr. Erik Thunnissen,a prominent clinician and opinion leader in the field of Humanpapillomavirus," said Mr. Fareed Kureshy, President and CEO of AutoGenomics.He further said that "with increasing demands for alternative technologies tomeet the evolving need for genotyping we are excited that we can offer anautomated solution that can significantly enhance workflow efficiency in thelaboratory".
Advertisement
About AutoGenomics
AutoGenomics Inc., a privately held company based in Carlsbad, CA., hasdeveloped the first automated, microarray based multiplexing diagnosticplatform that can be used to assess disease signatures with novel genomic andproteomic markers in the area of genetic disorders, infectious disease, cancerand pharmacogenetics. With the discovery of genes and their link to variousdisease states the platform has the versatility to revolutionize the waypatients are diagnosed, monitored and managed, leading to the era ofpersonalized medicine. www.autogenomics.com
SOURCE AutoGenomics Inc.
